

Coordonnateur européen du projet	Acronyme du projet	Titre du projet	Responsable de l'équipe française associée (le cas échéant)	Cancéropôle de référence
GENNARI Alessandra Ente Ospedaliero Ospedali Galliera Genova-Italie	ET-FES	Early prediction of efficacy of endocrine therapy in breast cancer: pilot study and validation with 18F Fluoroestradiol (FES) PET/CT	BRAIN Étienne Hôpital René Huguenin - Institut Curie Saint-Cloud - France	Cancéropôle Ile de France-PARIS
BONDANZA Attilio San Raffaele Scientific Institute Milano-Italie	HAPLO-IMMUNE	Validation of immune biomarkers predictive of clinical outcome after HLA-haploidentical hematopoietic stem cell transplantation for acute leukemia	TOUBERT Antoine Université Denis Diderot Paris 7- Hôpital Saint Louis Paris - France	Cancéropôle Ile de France-PARIS
PANTEL Klaus University Hospital of Hamburg Hamburg-Allemagne	CTC-SCAN	Circulating Tumor Cells as Biomarker for Minimal Residual Disease in Prostate Cancer	ALIX-PANABIERES Catherine CHU Montpellier - Hôpital Saint Eloi Montpellier - France	Cancéropôle Grand-Sud-Ouest-TOULOUSE
ANDRE Fabrice Institut Gustave Roussy (IGR) Villejuif-France	UGI1	CD3 and CD20 lymphocytes infiltration to predict chemosensitivity in patients with triple negative breast cancer	BONNEFOI Hervé Institut Bergonié - Unicancer Bordeaux - France	Cancéropôle Ile de France-PARIS
DIRKSEN Uta University Children's Hospital Münster Munster-Allemagne	PROVABES	PROsPROspective VALidation of Biomarkers in Ewing Sarcoma for personalised translational medicine	DELATTRE Olivier Institut Curie Paris - France	Cancéropôle Ile de France-PARIS
STANULLA Martin University Hospital Schleswig Holstein Kiel - Allemagne	TRANSCALL	Validation of the impact of genetic aberrations and host genetic variation in childhood acute lymphoblastic leukemia for integration into clinical practice	CAVE Hélène Hôpital Robert Debré - APHP Paris - France	Cancéropôle Ile de France-PARIS
ARANGO Diego Vall d'Hebron University Hospital Research Institute Barcelona - Spain	VALPRAXIN	Validation of Aprataxin as a biomarker of response to Topoisomerase I inhibitors in cancer patients		
GARASSINO Marina Chiara Fondazione IRCSS ISTITUTO NAZIONALE DEI TUMORI Milan - Italie	Bio RaRE	K-RAS Mutations and DNA repair function in Non Small Cell Lung Cancer (NSCLC)		
PILS Dietmar Medical University of Vienna Vienna - Austria	ImPECT	Immune Cells as Predictors for Early Diagnosis and Chemotherapy Toxicity in Ovarian Cancer		
HUBALEWSKA-DYDEJCZYK Alicja Jagiellonian University Medical College Kraków - Poland	GRAN-T-MTC	Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma		